FDA Streamlines Biosimilar Testing, Slashing Drug Costs

Groundbreaking Developments in Health and Pharmaceutical Sector | Health

Devdiscourse2026.03.11Updated 34d ago

The US Food and Drug Administration FDA has introduced new guidelines intended to streamline biosimilar drug testing dramatically reducing the cost of vital biologic medications used in treating diseases such as cancer Despite these drugs accounting for 5 of prescriptions their cost represents 51 of total drug expenditure

AI SummaryPowered by AI

The FDA has introduced new guidelines to streamline biosimilar drug testing, dramatically reducing costs for vital biologic medications used in cancer treatment and other diseases. Despite biosimilars representing only 5% of prescriptions, they account for 51% of total drug expenditure. These regulatory changes aim to make life-saving treatments more accessible and affordable.

Key topics:fda biosimilar drugs drug testing guidelines cancer treatment biologic medications

Original Article

Read full article on Devdiscourse